Carbonate ion

Unicycive Therapeutics announced Phase 1 study results for oxylanthanum carbonate (OLC) in healthy volunteers, showing it's well-tolerated and reduces phosphate absorption. The data supports OLC's New Drug Application under FDA review, with a decision expected by June 28, 2025. OLC aims to treat hyperphosphatemia in chronic kidney disease patients.

Unicycive Therapeutics' oxylanthanum carbonate Phase 1 study in healthy volunteers showed the drug was well tolerated, reduced phosphate absorption, and had no serious adverse events. The study involved 32 participants across four dose levels, demonstrating safety and dose-dependent decreases in urinary phosphorus excretion.

Unicycive Therapeutics announced Phase 1 study results for oxylanthanum carbonate (OLC), showing it's well-tolerated and reduces phosphate absorption in healthy volunteers. OLC, targeting hyperphosphatemia in CKD patients, is under FDA review with a PDUFA date of June 28, 2025. The study demonstrated OLC's safety and dose-dependent phosphate-binding capacity.

Unicycive Therapeutics announced Phase 1 study results for oxylanthanum carbonate (OLC), showing it's well-tolerated and reduces phosphate absorption in healthy volunteers. OLC, targeting hyperphosphatemia in CKD patients, is under FDA review with a PDUFA date of June 28, 2025.

Unicycive Therapeutics announced the publication of its oxylanthanum carbonate (OLC) bioequivalence study in Clinical Therapeutics, showing OLC's equivalence to Fosrenol® in healthy volunteers. OLC, a next-gen phosphate binder, is under FDA review with a potential 2025 launch. It aims to treat hyperphosphatemia in CKD patients, offering lower pill burden and better compliance.

Unicycive Therapeutics announced bioequivalence of Oxylanthanum Carbonate (OLC) to Fosrenol®, with data published in Clinical Therapeutics. OLC, a phosphate binder for hyperphosphatemia in kidney disease, showed similar efficacy and tolerability to lanthanum carbonate in a study with 75 participants. Unicycive is preparing for OLC's 2025 commercial launch, pending FDA approval.

Unicycive Therapeutics announced bioequivalence of oxylanthanum carbonate (OLC) to Fosrenol® in a study published in Clinical Therapeutics. OLC, a phosphate binder for hyperphosphatemia in kidney disease, showed similar efficacy and tolerability to lanthanum carbonate. Unicycive is preparing for OLC's commercial launch in 2025, pending FDA approval.